Financial toxicity of radiotherapy for multiple brain metastases: Will it get worse or better?
Status PubMed-not-MEDLINE Language English Country Great Britain, England Media electronic-ecollection
Document type Editorial
PubMed
37457223
PubMed Central
PMC10346388
DOI
10.1093/nop/npad018
PII: npad018
Knihovny.cz E-resources
doi: 10.1093/nop/npac093 PubMed
See more in PubMed
Meyers CA, Rock EP, Fine HA.. Refining endpoints in brain tumor clinical trials. J Neurooncol. 2012;108(2):227–230. PubMed
Patchell RA, Tibbs PA, Regine WF, et al. . Postoperative radiotherapy in the treatment of single metastases to the brain: A randomized trial. JAMA. 1998;280(17):1485–1489. PubMed
Kazda T, Jancalek R, Pospisil P, et al. . Why and how to spare the hippocampus during brain radiotherapy: The developing role of hippocampal avoidance in cranial radiotherapy. Radiat Oncol. 2014;9:139. PubMed PMC
Hussaini SMQ, Gupta A, Dusetzina SB.. Financial toxicity of cancer treatment. JAMA Oncol. 2022;8(5):788. PubMed
Chen VE, Kim M, Nelson N, et al. . Cost-effectiveness analysis of three radiation treatment strategies for patients with multiple brain metastases. Neurooncol Pract. 2023;10(4):344–351. PubMed PMC
Dong L, Lin S, Zhong L, et al. . Evaluation of tucatinib in her2-positive breast cancer patients with brain metastases: A united states-based cost-effectiveness analysis. Clin Breast Cancer. 2022 Jan;22(1):e21–e29. PubMed
